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T cells are the central mediators of adaptive immunity. The unique 
specificity of each naïve T cell is determined by the T-cell receptor 
(TCR), which binds antigenic peptides presented on the surface of 
a target cell by major histocompatibility complex (MHC) molecules. 
The affinity of the TCR for a monomeric peptide–MHC (Kd ≈ 
0.1–400 mM) is much weaker than the nanomolar affinity of a typical 
antibody–antigen interaction (1). To enable direct and stable labeling 
of antigen-specific T cells, Davis and colleagues assembled four bioti-
nylated peptide–MHC (pMHC) monomers non-covalently around 
a fluorescently labeled, tetrameric streptavidin core (2) (Figure 1A). 
This pMHC tetramer exploits avidity to reduce the off-rate of TCR–
pMHC interactions, enabling detection and monitoring of antigen-
specific T-cell subsets via multicolor flow cytometry. However, T cells 
bearing low-affinity TCRs (>80 mM) are poorly detected using pMHC 
tetramers (3). This is particularly problematic for detection of T cells 
mediating autoimmunity and anti-tumor immunity, as thymic selection 
eliminates T cells with high affinity for non-mutated self-antigens (1,4).
Increasing the avidity of pMHC multimers beyond that of tetramers 
improves detection of low-affinity T cells. For instance, high-valency 
pMHC multimers such as dextramers and the recently described 
dodecamers enable detection of 2- to 5-fold more specific CD8+ T 
cells than do corresponding tetramers (5,6). Currently, commercial 
pMHC dextramers (Immudex) are constructed by assembling bioti-
nylated pMHC monomers around a dextran scaffold functionalized 
with both streptavidin and fluorochrome (Figure 1A). This dual-
functionalized dextran is not available as a commercial product, 
and ready-to-use dextramers are expensive reagents ($1250/50 
tests; Immudex). Additionally, the covalent conjugation of streptavidin 
and fluorochrome to the dextran scaffold precludes the flexibility 
afforded by commercial streptavidin reagents (i.e., the large variety 
of fluorochrome-streptavidin conjugates available).
Here, we describe a simple and inexpensive protocol for producing 
dextramers. Streptavidin-fluorochrome is bound to a sub-stoichio-
metric number of biotinylated pMHCs or biotinylated TCRs, leaving 
some streptavidin sites available for binding additional biotin 
groups. Biotinylated high-molecular-weight dextran is then doped 
into the binding reaction, resulting in the assembly of high-valency 
dextramers. We demonstrate that the resulting pMHC dextramers or 
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Peptide–major histocompatibility complex (pMHC) multimers enable the detection, characterization, and isolation 
of antigen-specific T-cell subsets at the single-cell level via flow cytometry and fluorescence microscopy. These 
labeling reagents exploit a multivalent scaffold to increase the avidity of individually weak T-cell receptor (TCR)-
pMHC interactions. Dextramers are an improvement over the original streptavidin-based tetramer technology 
because they are more multivalent, improving sensitivity for rare, low-avidity T cells, including self/tumor-reactive 
clones. However, commercial pMHC dextramers are expensive, and in-house production is very involved for a 
typical biology research laboratory. Here, we present a simple, inexpensive protocol for preparing pMHC dext-
ramers by doping in biotinylated dextran during conventional tetramer preparation. We use these pMHC dextra-
mers to identify patient-derived, tumor-reactive T cells. We apply the same dextran doping technique to prepare 
TCR dextramers and use these novel reagents to yield new insight into MHC I–mediated antigen presentation.
Reports
METHOD SUMMARY
Here, we present a simple, inexpensive protocol for preparing peptide–major histocompatibility complex (pMHC) dextramers. 
Streptavidin is assembled with a sub-stoichiometric number of biotinylated pMHC molecules, and the remaining available biotin-
binding sites enable subsequent high-valency assembly on a biotinylated dextran scaffold. This flexible protocol can be used with 
various fluorochrome-conjugated streptavidins as well as with other biotinylated molecules, including T-cell receptors (TCRs).
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TCR dextramers can be used to detect and monitor low-affinity (tumor) 
antigen-reactive T-cell subsets or to study antigen presentation.
Materials and methods
Primers were purchased from Integrated DNA Technologies (Coralville, 
IA). KOD Hot Start Master Mix (containing KOD Hot Start Polymerase) 
and R-1003-G Polybrene Infection/Transfection Reagent were 
purchased from EMD Millipore (Darmstadt, Germany). Sequencing 
was performed by Retrogen Inc. (San Diego, CA). Fluorescently 
labeled antibodies used for flow cytometry were purchased from 
Biolegend (San Diego, CA). Anti-CD3 (OKT3) and anti-CD28 (CD28.2) 
activating antibodies were purchased from eBioscience (San Diego, 
CA). Cytokines were purchased from Peprotech, Inc. (Rocky Hill, NJ). 
Concanavalin A was purchased from Sigma-Aldrich (St. Louis, MO). 
RetroNectin was purchased from Clontech Laboratories (Mountain 
View, CA). BioT transfection reagent was purchased from Bioland 
Scientific (Paramount, CA). Cell culture media, antibiotics, and fetal 
bovine serum (FBS) were purchased from Corning (Corning, NY). 
Human AB serum was purchased from Omega Scientific (Tarzana, 
CA). Peptides were purchased from Anaspec (San Jose, CA). Biotin 
ligase (BirA) was prepared and used to biotinylate pMHC and TCR 
molecules as described previously (7).
Cell lines and primary cells
HEK 293T/17, Jurkat E6–1, and K562 cells were obtained from the 
American Type Culture Collection (Manassas, VA). Their identities 
were authenticated by STR analysis, and they were confirmed to be 
mycoplasma-free (DDC Medical, Fairfield, OH). HEK 293T/17 cells were 
grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 10% (v/v) FBS and the antibiotics penicillin/streptomycin (pen/
strep; 100 IU/mL pen, 100 mg/mL strep). Jurkat and K562 cells were 
grown in RPMI 1640 medium supplemented with 10% (v/v) FBS, 50 
mM b-mercaptoethanol, 1× MEM non-essential amino acids (NEAA), 
10 mM HEPES, 1 mM sodium pyruvate, and antibiotics (pen/strep). The 
HLA-A2+ K562 line (Kv701) was derived from the K562 line by trans-
ducing the cells with a lentiviral vector encoding HLA-A2 and ZsGreen, 
and then sorting for these markers. All cell lines were grown at 37°C 
with 5% atmospheric CO2, and were split every 2–3 days. Primary 
human peripheral blood mononuclear cells (PBMCs) were purchased 
from the CFAR Virology Core Lab at the UCLA AIDS Institute. PBMCs 
from a patient with advanced melanoma were obtained through leuka-
pheresis under UCLA IRB approval 10–001598 and viably cryopre-
served in aliquots until use as previously described (8).
Peptide–MHC multimers 
Biotinylated H-2Kb/ovalbumin257–264 monomers were provided by the 
NIH Tetramer Core Facility (Atlanta, GA). HLA-A2 and b2-microglobulin 
were expressed in E. coli, refolded in the presence of peptide [MART126–
35(A27L) (ELAGIGILTV); NYESO1157–165(C165V) (SLLMWITQV); or UV-cleavable 
J-ligand for HLA-A2 (GILGFVFJL; J = 3-amino-3-(2-nitro)phenyl-
propionic acid)], purified, and biotinylated as previously described (7). 
Peptide–MHC monomers were stored at -20°C or -80°C until use.
Peptide–MHC tetramers were prepared from monomers using 
fluorescently labeled streptavidin from Molecular Probes (Eugene, 
OR) according to the NIH Tetramer Core Facility protocol. One equiv-
alent (eq) (2.5 µM final) of streptavidin-fluorochrome [either phycoery-
thrin (PE) or allophycocyanin (APC)] was added over 10 × 10 min time 
intervals to 4 eq biotin-pMHC (10 µM final). Peptide–MHC dextramers 
were prepared by doping the tetramer assembly reaction with bioti-
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nylated dextran. Briefly, peptide–MHC and fluorescently labeled strep-
tavidin were added at a molar ratio of 3:1 (7.5 mM : 2.5 mM final) and 
incubated 10 min. Biotinylated dextran, molecular weight (MW) 500 
kDa (Molecular Probes) was then added to the incubation at 1:20 with 
respect to streptavidin (125 nM final) and incubated an additional 10 
min. Peptide–MHC multimers were prepared fresh or stored briefly (<1 
week) at 4°C. We attempted to use high-performance size-exclusion 
chromatography/multiangle light-scattering (HPSEC-MALS) to measure 
the average number of streptavidin molecules bound per dextran 
scaffold, but due to the large size, shape, and heterogeneity of the 
commercial dextran molecules, we were unable to determine this 
parameter.
Commercial dextramers for H-2Kb/ovalbumin257–264 (SIINFEKL), 
HLA-A2/MART126–35(A27L) (ELAGIGILTV), and HLA-A2/MART126–35(A27L) 
(ELAGIGILTV) were purchased from Immudex (Copenhagen, Denmark) 
and used within 1 month of receipt.
TCR multimers
Soluble TCR monomers were prepared as described (9), with several 
modifications. A His6 tag was fused to the C terminus of the TCRa 
ectodomain to enable purification by Ni-NTA (QIAGEN, Hilden, 
Germany), and the 15-amino-acid AviTag BirA substrate sequence 
(10) was fused to the C terminus of the TCRb ectodomain to enable 
biotinylation. TCRa and TCRb inclusion body pellets from E. coli were 
dissolved in inclusion body solubilization buffer (8 M urea, 25 mM 
MES pH 6.0, 10 mM EDTA, 0.1 mM DTT) and stored at -80°C until 
refolding. M1 TCRa dissolved poorly in 8 M urea and was instead 
dissolved in solubilization buffer containing 6 M guanidine hydrochloride 
(GnHCl).  Thirty milligrams each of TCRa and TCRb were diluted into 
500 mL refolding buffer [3 M urea, 0.2 M Arg-HCl, 150 mM Tris-HCl 
pH 8.0, 1.5 mM reduced glutathione, 0.15 mM oxidized glutathione, 
protease inhibitor cocktail (Roche, Basel, Switzerland), and 1 mM PMSF 
(added daily)] and stirred at 4°C for 72 h. Refolded TCR was dialyzed 
in SnakeSkin dialysis tubing (10,000 Da MWCO) (cat#68100; Thermo-
Fisher, Waltham, MA) at 4°C for 24 h in 4 L dialysis buffer (10 mM Tris 
pH 8.5, 50 mM NaCl) and then for an additional 24 h in fresh 4 L dialysis 
buffer. Dialyzed TCR was both concentrated and initially purified using 
Ni-NTA, further concentrated with centrifugal filters (30,000 MWCO, 
EMD Millipore), and then purified by size-exclusion chromatography. 
Purified TCR monomers were enzymatically biotinylated with BirA as 
described for pMHC (7), purified by size-exclusion chromatography, 
concentrated, supplemented with glycerol to 18%, and stored at -20°C 
or -80°C until use. TCR tetramers and dextramers were assembled 
analogously to pMHC tetramers and dextramers.
Determination of TCR–pMHC binding affinity
The affinities of the M1, 1G4, and F5 TCRs for their respective pMHC 
ligands were determined by surface plasmon resonance using a 
Biacore T200 biosensor instrument (Uppsala, Sweden). Streptavidin 
was immobilized via amine coupling on a Series S Sensor chip CM5 
General Electric (Fairfield, CT) and then biotinylated peptide–MHC 
complex was bound to the chip at 100 nM [Cell 1: no pMHC; Cell 2: 
HLA-A2/InfluenzaM158–66 (GILGFVFTL); Cell 3: HLA-A2/MART126–35(A27L) 
(ELAGIGILTV); and Cell 4: HLA-A2/NYESO1157–165(C165V) (SLLMWITQV)]. 
The chip was flooded with 1 mM d-biotin to block the remaining strep-
tavidin, and then varied concentrations (15 mM–0.47 mM) of biotinylated 
TCR were flowed over all cells of the chip to measure TCR–pMHC 
binding. Cell 1 (blocked streptavidin only; no pMHC) was used for 
background subtraction, and kinetic constants were determined by 
fitting the data to a 1:1 Langmuir curve. The Kd values determined for 
F5 TCR/HLA-A2/MART126–35(A27L) (ELAGIGILTV) (5.4 mM) and 1G4 
TCR/HLA-A2/NYESO1157–165(C165V) (SLLMWITQV) (4.3 mM) were similar 
to those previously reported (11,12). Antigen-specific binding was 
detectable for M1 TCR/HLA-A2/MART126–35(A27L) (ELAGIGILTV), but an 
exact Kd was not determined (reported as >15 mM). Cross-reactivity of 
M1 or F5 for A2/NYESO1 or of 1G4 for A2/MART1 was not detectable.
TCR and pMHC single-chain trimer (SCT) viral vector constructs
OTI TCR, M1 TCR, 1G4 TCR, and F5 TCR retroviral constructs were 
generated as described (13). Peptide–MHC single-chain trimer (SCT) 
lentiviral constructs of NYESO1(SLLMWITQV)-b2m-HLA-A2 and 
MART1(ELAGIGILTV)-b2m-HLA-A2 were prepared with a disulfide 
trap modification as described(14).
Optimization of pMHC dextramer assembly and staining protocol
Tetramer preparation was performed per the standard NIH protocol, 
as detailed above. Dextramer preparation was performed as above 
except the ratios of biotinylated pMHC and biotinylated dextran to 
Figure 1. Design and optimization of dextran doping strategy for dextramer 
assembly. (A) Schematic comparing dextran doping to existing approaches 
for preparing peptide–major histocompatibility complex (pMHC) multimers. 
Equivalents (eq) are with respect to streptavidin. (B) Flow cytometry analysis 
of pMHC (HLA-A2/MART1) multimer binding by CD3+ HEK 293T/17 cells 
transfected with a cognate (high-affinity F5 or low-affinity M1) or control (1G4) 
TCR. Multimers were prepared with the indicated molar equivalents of biotin-
pMHC and dextran relative to streptavidin-fluorochrome conjugate [allophy-
cocyanin (APC)]. (C) Flow cytometry analysis of pMHC dextramer H-2Kb/Ova 
binding by CD3+ HEK 293T/17  cells transfected with the cognate (OTI) or 
control (F5) TCR. Data are triplicate measurements from a single experiment.
REPORTS
streptavidin-allophycocyanin (APC) were varied as shown. HEK 
293T/17 cells (50,000 cells/96-well plate well) were transfected with 
0.1 mg DNA (0.02 mg each of plasmids encoding TCRab-IRES-
ZsGreen, CD3d, CD3e, CD3g, and CD3z) using BioT transfection 
reagent according to manufacturer’s instructions. Medium was 
refreshed after 24 h. Cells were de-adhered from the plate 48 h 
after transfection using 2 mM EDTA in PBS and then stained for 
flow cytometry analysis with tetramer or dextramer preparations 
diluted 1:50 in FACS buffer (2% FBS in PBS).
To optimize the staining protocol, HEK 293T/17 cells were 
transfected as described above with 0.1 mg DNA [0.05 mg each of 
plasmids encoding TCRab-IRES-ZsGreen (murine OTI or human 
F5) and murine CD3(degz)]. Transfected cells were stained for 
flow cytometry analysis with varying dilutions of H-2Kb/Ova257–264 
(SIINFEKL) dextramer purchased from Immudex or prepared 
in-house by biotinylated dextran doping.
Multimer staining of TCR-transduced primary human T cells
Murine stem cell virus (MSCV)-based retroviral vectors encoding 
LNGFRD-P2A-TCRa-F2A-TCRb (LNGFRD is a cell-surface trans-
duction marker) were produced in HEK 293T/17 cells as described 
previously (13). Primary T cells from human PBMCs were transduced 
in the presence of 10 mg/mL polybrene following activation with 1 
mg/mL plated anti-CD3 (OKT3), 1 mg/mL anti-CD28, and 300 U/
mL IL-2 in T-cell media [AIM-V media supplemented with 5% (v/v) 
human AB serum and antibiotics (pen/strep)].  Transduced primary 
T cells were stained with antibodies and either pMHC tetramers or 
pMHC dextramers. Stained CD8+ and CD8- T cells were analyzed 
for multimer binding by flow cytometry.
UV-exchange dextramer preparation and testing
Biotinylated HLA-A2/J-ligand (GILGFVFJL) was diluted to 2 µM in PBS 
and exposed to UV light (365 nm) for 1 h in the presence of 200 µM 
exchange peptide as described previously (7).  Following UV exchange, 
pMHCs were assembled into tetramers through 4 additions (at 10 min 
intervals) of streptavidin-APC to a final ratio of 4:1::pMHC:streptavidin. 
Alternately, streptavidin-APC was added in a single step to a final 
ratio of 3:1::pMHC:streptavidin and incubated 10 min; biotinylated 
dextran was then added to a final ratio of 0.05:1::dextran:streptavidin. 
Jurkat T cells transduced with retrovirus encoding LNGFRD-
P2A-TCRa-F2A-TCRb (either 1G4 TCR or F5 TCR) were stained 
for flow cytometry with UV-exchanged tetramers or dextramers.
Detection of low-frequency tumor-specific T cells from PBMCs
PBMCs were obtained through leukapheresis from a patient with 
metastatic melanoma, which had been previously described to 
contain up to 5% MART-1-specific CD8+ T cells (8). Viably frozen 
cells were thawed and resuspended in FBS containing APC-labeled 
commercial dextramer (1:20 dilution), tetramer prepared in-house 
(1:200 dilution), or dextramer prepared in-house by dextran doping 
(1:200 dilution). After 15 min at room temperature, an antibody mix 
was added containing anti-CD3e(clone OKT3)-Brilliant Violet 421, 
anti-CD8a(clone SK1)-Brilliant Violet 510, anti-CD16(clone 3G8)-FITC, 
anti-CD19(clone HIB19)-FITC, and anti-CD4(clone RPA-T4)-APC-Cy7, 
all diluted to 1:100. Cells were incubated with antibody for 15 min 
on ice, then washed, centrifuged, and resuspended in FACS buffer 
containing 7-aminoactinomycin D (7-AAD) (00-6993-50; eBioscience, 
Inc., San Diego, CA). Cells were analyzed by flow cytometry to measure 
the percentage of live CD3+CD8+ T cells specific for A2/MART1.
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Detection of surface pMHC on peptide-loaded  
K562 cells using TCR dextramers
HLA-A2+ K562 cells were incubated with varying concentrations (16 
nM–50 mM) of peptide for 2 h at 37°C. The peptide-loaded HLA-A2+ 
cells were then washed, stained with APC-labeled TCR tetramer or 
TCR dextramer (1:50 dilution), and then analyzed by flow cytometry.
Detection and resolution of single-chain trimer 
pMHC clusters using TCR dextramers
K562 cells were transduced with lentiviral vectors encoding peptide–
MHC single-chain trimers (NYESO1(SLLMWITQV)-b2m-HLA-A2, 
MART1(ELAGIGILTV)-b2m-HLA-A2, or both vectors). Transduced cells 
were stained with 1G4 TCR dextramer-PE and F5 TCR dextramer-APC, 
and then analyzed by flow cytometry. For microscopy experiments, 
SCT-transduced K562 cells were stained with 1G4 TCR dextramer-
AlexaFluor555 and F5 TCR dextramer-AlexaFluor647. Cell images 
were taken with an objective-type total internal reflection fluorescence 
microscope (Olympus X81; Olympus Life Science Solutions, Center 
Valley, PA) and analyzed with ImageJ.
Statistics
Significance analysis of tumor-specific T-cell multimers staining was 
conducted with one-way analysis of variance and Tukey’s post-test 
for multiple comparisons. A statistical probability of P < 0.05 was 
considered significant. Descriptive statistics are presented throughout 
the figures as mean ± SD of replicate assays.
Results and discussion
We devised a simple strategy to produce pMHC dextramers: Strep-
tavidin-fluorochromes assembled with sub-stoichiometric amounts 
of biotinylated pMHC molecules are subsequently assembled via 
their remaining open binding sites on a biotinylated dextran scaffold 
(Figure 1A). This dextran doping strategy has several advantages 
over the current protocol for pMHC-dextramer assembly.  First, it 
is inexpensive and uses only commercially available reagents and 
biotinylated monomers that can either be made in-house or obtained 
without charge from the NIH Tetramer Core Facility. Second, the strep-
tavidin and fluorochrome are not conjugated to the dextran core. 
Thus, dextran doping can be used with a wide variety of commer-
cially available streptavidin-fluorochrome conjugates. Used in concert 
with UV-mediated peptide exchange (7) and multicolor combinatorial 
encoding (15), dextran doping enables construction of panels of pMHC 
dextramers for parallel detection of multiple low-affinity T-cell speci-
ficities. Third, this general protocol can be used to multimerize other 
interesting molecules (e.g., the TCR) to construct reagents that are 
not available commercially.
To optimize the dextramer assembly protocol, we varied the ratio of 
biotinylated pMHC (HLA-A2/MART1ELAGIGILTV) molecules per fluorescent 
streptavidin molecule, then doped in various equivalents of biotinylated 
dextran. The resulting reagents were tested for their capacity to label 
HEK 293T/17 cells displaying either cognate TCR (A2/MART1-specific 
M1 and F5) or non-cognate TCR (A2/NYESO1-specific 1G4) (Figure 
1B). Four conclusions can be drawn from this experiment. First, dextran 
doping increased the intensity of labeling compared with conven-
tional tetramer staining for cognate TCR–expressing HEK 293T/17 
cells. Second, the difference in staining intensity between tetramer 
and various dextramer preparations was larger for the low-affinity 
M1 TCR (5.5–11.7 fold) than that for the high-affinity F5 TCR (2.5–3.8 
fold). Third, neither the A2/MART1 tetramer nor any of the prepa-
rations of dextramer bound to non-cognate 1G4 TCR–transfected 
HEK 293T/17 cells, indicating that dextran doping does not impair the 
specificity of binding. Finally, the staining intensity did not vary greatly 
across dextramer preparations (<2 fold), indicating that the high avidity 
resulting from dextran doping renders staining intensity robust toward 
the number of biotinylated-pMHC bound to each individual strepta-
vidin. Notwithstanding this, we identified ratios of 3:1::pMHC:streptavidin 
and 0.05:1::dextran:streptavidin as optimal for dextramer assembly.
We next sought to evaluate the efficiency and specificity of cell 
staining with dextramers prepared by dextran doping. We prepared 
murine H-2Kb/Ova dextramers according to the optimized protocol 
described above and varied the dextramer dilution used to stain HEK 
293T/17 cells displaying either cognate TCR (H-2Kb/Ova-specific OTI) 
or non-cognate TCR (F5) (Figure 1C). H-2Kb/Ova dextramer staining 
was specific and titratable, demonstrating that dextran doping can be 
Figure 2. Dextran doping improves 
detection of low-affinity/tumor-
reactive T cells. (A) Flow cytom-
etry of peptide–major histocom-
patibility complex (pMHC) (HLA-
A2/MART1) multimer binding by 
primary T cells transduced with 
cognate (high-affinity F5 or low-
affinity M1) or control (1G4) T-cell 
receptor (TCR).  (B) Flow cytom-
etry comparing exchange pMHC 
multimer binding by Jurkat T cells 
transduced with cognate (F5) 
or control (1G4) TCR. Tetramers 
and dextramers were assembled 
following UV-mediated exchange 
of HLA-A2/J-ligand with 100-fold 
excess of the indicated peptide. 
Means ± SD for three replicate 
transductions are shown. (C) Flow 
cytometry of melanoma-reactive 
primary T cells collected by leu-
kapheresis from a patient with 
melanoma. Means ± SD for three 
replicate experiments are shown. 
*, P < 0.05; **, P < 0.01; ****, 
P < 0.0001; ns, not significant.
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applied to the assembly of murine pMHC multimers. We determined 
that a dilution of 1:200–1:50 is optimal for dextramers generated by 
dextran doping, yielding staining intensity comparable to or better 
than commercial H-2Kb/Ova dextramer. To compare non-specific 
background staining, primary human CD8+ T cells were stained with A2/
MART1 and A2/NYESO1 dextramers prepared in-house or purchased 
from Immudex. Background staining with in-house dextramers was 
not significantly higher than with commercial dextramers (0.11 ± 0.02% 
versus 0.06 ± 0.07%, P = 0.31 for A2/MART1 dextramer; 0.24 ± 0.18% 
versus 0.02 ± 0.04%, P = 0.17 for A2/NYESO1).
Straightforward assembly of dextramers will be particularly useful 
for the fields of cancer immunology and immunotherapy. Dextramers 
of class II pMHC molecules improve detection of antigen-specific 
CD4+ T cells (16), which are emerging as important components of 
anti-tumor immunity (17,18) and are generally lower-affinity than CD8+ 
T cells(19). Moreover, TCRs derived from tumor-reactive CD8+ T cells 
are constrained by thymic selection to a low-affinity range (1,4) and 
are generally assisted in pMHC recognition by CD8:MHC I interaction 
(20). We transduced PBMCs with TCRs of varying affinity for A2/
MART1 to determine the extent to which dextran doping improves 
pMHC multimer staining of low- and high-affinity TCRs expressed 
on CD8+ or CD8- T cells. A2/MART1 dextramers did not bind T cells 
transduced with the non-cognate 1G4 TCR, confirming the speci-
ficity of these reagents in the context of primary T-cell staining (Figure 
2A). By contrast, dextramers improved antigen-specific staining of 
cognate TCR–transduced T cells relative to tetramers. The extent of 
this improvement ranged from 2.4-fold for high-affinity TCRs on CD8+ 
T cells to 5.7-fold for low-affinity TCRs on CD8- T cells, the latter of 
which could not be discerned from background by tetramer staining.
The ability to assemble a multiplexed panel of pMHC tetramers 
using UV-exchangeable peptide ligands constitutes a key advance 
for the characterization and isolation of tumor-specific T cells 
(7). To determine if dextran doping enables combination of the 
improved sensitivity of pMHC dextramers with pMHC UV-exchange 
technology, we prepared biotinylated HLA-A2 monomers bound to 
a UV-exchangeable peptide, irradiated the monomer in the presence 
of MART1 or NYESO1 peptide, prepared tetramers or dextran-doped 
dextramers with the exchanged monomers, and then used the 
resulting multimers to stain TCR-transduced Jurkat T cells. Similar 
to conventional multimer staining of primary CD8- T cells (Figure 2A), 
UV-exchanged dextramers stained F5 TCR–transduced, CD8- Jurkat 
T cells with a 3.2-fold higher mean fluorescence intensity (MFI) than 
UV-exchanged tetramers (Figure 2B). Binding was dependent on 
UV-exchange with MART1 ligand, and no binding was observed 
to cells transduced with a non-cognate TCR. Thus, dextran doping 
can be combined with pMHC UV-exchange technology to produce 
multimer panels with comparable specificity to and higher sensitivity 
than UV-exchanged tetramers.
To determine whether dextran-doped dextramers improve 
detection of T cells involved in endogenous anti-tumor immunity, 
we used tetramers or dextramers to stain PBMCs isolated from a 
melanoma patient whose peripheral repertoire was previously charac-
terized to contain MART1-specfic T cells at a frequency of ~5% (8). 
While MART1-specific T cells were detectable using conventional 
tetramers, dextran doping improved the staining of these cells 2.6-fold 
(Figure 2C). Staining with dextran-doped dextramers was comparable 
to staining with commercial dextramers, suggesting dextran doping 
can be used to detect low-affinity T cells with significant cost savings 
compared with commercial dextramers.
Dextran doping is a general approach that can be used to increase 
non-covalent multimerization of any biotinylated molecule. Previous 
results showed that TCR tetramers enable specific and quanti-
tative staining of target cells presenting cognate antigen, compet-
itive blockade of T-cell-mediated immune responses, and potentially 
antigen-directed drug delivery (21–23). Multimerized TCRs can also 
be used to study TCR cross-reactivity and to discover peptide ligands 
for orphan TCRs (24–26). Thus, we produced TCR dextramers—
reagents for which there is no commercial source—to determine if 
these applications may be facilitated by increasing reagent valency. 
TCR dextramers were produced by dextran doping, analogously to 
the scheme used to produce pMHC dextramers (Figure 3A).
To determine whether TCR dextramers enable specific staining 
of targets presenting cognate antigen, the human erythroleukemic 
cell line K562 was transduced with HLA-A2, the derived cell line was 
pulsed with either NYESO1 or MART1 peptide, and peptide-pulsed 
cells were stained with either NYESO1-specific 1G4 TCR or MART1-
specific F5 TCR multimers. TCR multimers specifically stained those 
cells pulsed with their cognate peptide (Figure 3B). TCR dextramers 
improved staining over TCR tetramers for both specificities tested 
(7.9-fold for F5 TCR and 2.9-fold for 1G4 TCR). Dextramer staining 
Figure 3. T-cell receptor (TCR) dextramers improve antigen-specific target-
cell binding. (A) Schematic depicting TCR dextramer preparation using dex-
tran doping. TCR tetramer preparation is performed analogously to peptide–
major histocompatibility complex (pMHC) tetramer preparation as depicted in 
Figure 1A. (B) Overlay of flow cytometry histograms showing TCR (1G4 or F5) 
multimer binding by A2+ K562 cells pulsed with 50 mM NYESO1SLLMWITQV (left) 
or MART1ELAGIGILTV (right) peptide. Data are representative of three replicate 
experiments. (C) Flow cytometry of TCR (1G4 or F5) dextramer binding by A2+ 
K562 cells pulsed with varying concentrations of NYESO1SLLMWITQV or MAR-
T1ELAGIGILTV peptide. Means ± SD for three replicate experiments are shown.
A
B
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was quantitative, decreasing as the amount of pulsed peptide was 
titrated down (Figure 3C). Dextramer signal decreased precipitously 
at a peptide concentration of 2 mM and was undetectable at 0.4 mM 
and below. At these low levels of peptide, the density of cognate 
pMHC targets on the cell surface is too low for multivalent binding, 
so TCR dextramers are of limited utility. Importantly, these concen-
trations of pulsed peptide likely result in substantially more peptide 
presented on the cell surface than levels resulting from endogenous 
antigen processing. Indeed, we attempted to use F5 TCR dextramer to 
detect endogenously presented MART1 antigen from melanoma but 
were unsuccessful (data not shown). Thus, for applications requiring 
detection or targeting of endogenously expressed antigens, affinity-
matured soluble TCR reagents are better suited than multimerized 
TCR reagents, regardless of valency (27,28).
Although TCR dextramers cannot detect endogenously processed 
antigens, they may be useful for specific studies related to antigen 
processing. For example, a previous study described a phenomenon 
of segregated clustering of class I pMHC molecules bearing different 
peptides on the surfaces of target cells (29). Peptide-specific pMHC 
clustering required endogenous expression (i.e., it was not observed 
following exogenous peptide pulsing), and it preceded export to the 
cell surface (i.e., it was detectable in the Golgi apparatus). However, 
it was not clear at which stage of antigen processing clustering was 
initiated, nor was it determined if this clustering was dependent on 
proteasomal processing or TAP-mediated import to the endoplasmic 
reticulum. Single-chain trimers (SCTs) are synthetic constructs that 
genetically link a particular peptide to b2-microglobulin and an MHC 
I heavy chain as a single polypeptide chain (14). Due to this linkage, 
cell-surface expression of SCTs bypasses proteasomal processing 
and peptide loading. Moreover, because these molecules ensure 
presentation of the encoded peptide on every surface-expressed 
SCT, we presumed they would be presented at sufficient density 
to engage avidly with multimerized TCR reagents. Therefore, TCR 
dextramers may be used to investigate whether SCTs—like pMHCs—
are clustered on the target cell's surface in a peptide-specific manner.
We first determined whether TCR dextramers detect SCTs on the 
surfaces of target cells. We transduced K562 cells with A2/MART1 
SCT, A2/NYESO1 SCT, or both and assayed these derived cell lines 
by flow cytometry for binding to both F5 and 1G4 TCR dextramers. As 
expected, untransduced cells bound neither TCR reagent, transduced 
cells expressing only one SCT bound specifically to the cognate TCR 
reagent only, and transduced cells expressing both SCTs bound both 
TCR reagents (Figure 4A). We then used total internal reflection fluores-
cence (TIRF) microscopy to investigate the clustering of these SCT 
molecules on the K562 cell surface. Consistent with flow cytometry 
results, untransduced cells did not bind either TCR reagent while singly 
transduced cells bound only their cognate TCR (Figure 4B). Interestingly, 
cells transduced with both SCTs exhibited distinct clusters of A2/MART1 
and A2/NYESO1 SCT molecules, as evidenced by the lack of overlap 
between 1G4 and F5 TCR dextramer binding (Figure 4C). The impor-
tance of this result is two-fold. First, because SCTs bypass proteasomal 
processing, TAP-mediated transport to the endoplasmic reticulum, 
and peptide loading to the MHC, our data suggest that peptide-
specific clustering of pMHC molecules occurs independently of these 
processes. Second, determining the rules governing pMHC clustering 
will require pairwise clustering analyses of many different peptides, a 
challenging prospect if cognate soluble TCR reagents are required for 
each peptide tested. SCTs may facilitate this investigation because 
the genetic linkage between a specific peptide and MHC molecule 
bypasses the need for soluble TCRs (e.g., epitope-indexed SCTs bearing 
different peptides can be resolved using epitope-specific antibodies).
Here, we present a simple technique for producing pMHC and TCR 
dextramers by assembling streptavidin-fluorochrome conjugates with 
sub-stoichiometric amounts of biotinylated monomers, followed by 
doping the assembly reaction with a highly biotinylated dextran scaffold. 
Like commercial dextramers, these dextran-doped dextramers 
improve the sensitivity of antigen-specific T-cell detection relative to 
pMHC tetramers. The advantages of this approach over commercial 
dextramers are that dextran doping is: (i) inexpensive; (ii) easy to adopt in 
a biology or immunology lab setting; (iii) compatible with state-of-the-art 
Figure 4. T-cell receptor (TCR) 
dextramers detect peptide-spe-
cific clustering of peptide–ma-
jor histocompatibility complex 
(pMHC) single-chain trimers 
(SCTs). (A) Overlay of flow cytom-
etry plots showing dual staining 
(1G4 and F5 TCR dextramers) 
of K562 cells transduced with 
mock vector, A2/NYESO1 SCT, 
A2/MART1 SCT, or both SCTs. 
Data are representative of three 
replicate experiments. (B) TIRF 
microscopy showing K562 
cells mock transduced or singly 
transduced (A2/NYESO1 or A2/
MART1 SCT) and then stained 
with both 1G4 and F5 TCR dex-
tramers. Data are from a single 
experiment. (C) TIRF microscopy 
showing K562 cells transduced 
with both A2/NYESO1 and A2/
MART1 SCTs, then stained with 
both 1G4 and F5 TCR dextra-
mers. Multiple representative 
fields are shown from a single 
experiment. Images in (B) and (C) 
are overlays of two pseudocolored 
channels. Yellow indicates co-
localization of TCR dextramers.
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techniques (e.g., UV-mediated peptide exchange and multicolor combi-
natorial encoding), enabling monitoring of multiple antigen-specific 
T-cell subsets; and (iv) applicable to other biotinylated molecules—
such as TCRs—for which commercial sources of dextramers do not 
exist. The disadvantages of these reagents—which are shared with 
commercial dextramers—are two-fold. First, they rely on avidity and 
cannot bind stably to targets at a low density. For detection of endoge-
nously loaded pMHCs, higher-affinity reagents such as affinity-matured 
TCRs or TCR-like antibodies are required. Second, the number of 
pMHC and fluorochrome molecules bound per dextran molecule is 
not strictly controlled.  For highly quantitative studies, reagents that 
are molecularly defined may be better suited. Despite these caveats, 
our protocol presented should facilitate semi-quantitative studies 
requiring high-valency multimers of pMHCs or TCRs. As examples, we 
demonstrated the use of pMHC dextramers to detect tumor-reactive 
T cells from peripheral blood as well as the use of TCR dextramers 
to provide new insight into MHC I–mediated antigen presentation.
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